Non-adrenergic exploratory behavior induced by moxonidine at mildly hypotensive doses

Brain Research

Volumn 964, Issue 1, 2003, Pages 9-20

  Zhu, He ^a   Paul, Ian A ^a   Stec, David E ^a   Peeler, Dudley F ^a,c   Piletz, John E ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

2 Adrenoceptor; Anti depressant; Anxiety; Blood pressure; Exploration; Guanabenz; Imidazoline receptors; Moxonidine

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GUANABENZ; MOXONIDINE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; EXPLORATORY BEHAVIOR; FORCED SWIMMING TEST; HYPOTENSION; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEDATION; TASK PERFORMANCE;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; BLOOD PRESSURE; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EPINEPHRINE; EXPLORATORY BEHAVIOR; GUANABENZ; HYPERTENSION; HYPOTENSION; IMIDAZOLES; MALE; MICE; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG; SYMPATHETIC NERVOUS SYSTEM;

EID: 0037458517     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03754-X     Document Type: Article

References (58)

1. Armah B.I., Hofferber E., Stenzel W. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneim.-Forsch. 38:1988;1426-1434.
2. Benson H. Relaxation response, physiology, history and clinical applications. Adelman G. Encyclopedia of Neuroscience. Vol. II:1987;1045-1047 Birkhauser, Boston.
3. 2C-adrenoceptor-overexpressing mice are impaired in executing non-spatial and spatial escape strategies. Mol. Pharmacol. 54:1998;569-576.
4. Blaxall H.S., Murphy T.J., Baker J.C., Ray C., Bylund D.B. Characterization of the alpha-2C adrenergic receptor subtype in the opossum kidney and in the OK cell line. J. Pharmacol. Exp. Ther. 259:1991;323-329.
5. Buccafusco J.J. Neuropharmacologic and behavioral actions of clonidine: Interactions with central neurotransmitters. International Review of Neurobiology. Vol. 33:1992;55-107 Academic Press.
6. Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., Molinoff P.B., Ruffolo R.R. Jr., Trendelenburg U. International union of pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46:1994;121-136.
7. Chrisp P., Faulds D. Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. Drugs. 44:1992;993-1012.
8. 2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting. Cereb. Cortex. 11:2001;73-84.
9. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 13:1980;167-170.
10. 2 adrenoceptors in the human central nervous system. Neuroscience. 59:1994;589-598.
11. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., Dillon M.P. Seeing through a glass darkly: casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. 19:1998;381-390.
12. Elliott P.J., Chan J., Parker Y.M., Nemeroff C.B. Behavioral effects of neurotensin in the open field: structure-activity studies. Brain Res. 381:1986;259-265.
13. 1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla. Am. J. Physiol. 42:1997;R1572-R1579.
14. 1 imidazoline agonist. Cardiovasc. Drugs Ther. 8:1994;27-41.
15. 2 adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice. Pain. 84:2000;13-20.
16. 2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J. Pharmacol. Exp. Ther. 290:1999;403-412.
17. 1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats. Br. J. Pharmacol. 114:1995;751-754.
18. Grailhe R., Waeber C., Dulawa S.C., Hornung J.P., Zhuang X., Brunner D., Geyer M.A., Hen R. Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron. 22:1999;581-591.
19. 2-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch. Pharmacol. 327:1984;1-5.
20. 1-imidazoline receptors and cholinergic outflow to the airways. J. Auton. Nerv. Syst. 71:1998;167-174.
21. 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents. Ann. N Y Acad. Sci. 881:1999;279-286.
22. 2-adrenoceptors. Br. J. Pharmacol. 110:1993;1635-1639.
23. Hoffman J.W., Benson H., Arns P.A., Stainbrook G.L., Landsberg G.L., Young J.B., Gill A. Reduced sympathetic nervous system responsivity associated with the relaxation response. Science. 215:1982;190-192.
24. Hudson A., Price R., Tyacke R.J., Lalies M.D., Parker C.A., Nutt D.J. Harmane, norharmane and tetrahydro beta-carboline have high affinity for rat imidazoline binding sites. Br. J. Pharmacol. 126:1999;2P.
25. Jansson C.C., Marjamaki A., Luomala K., Savola J.-M., Scheinin M., Akerman K.E.O. Coupling of human alpha-2 adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells. Eur. J. Pharmacol. Mol. Pharmacol. 266:1994;165-174.
26. 2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain. Brain Res. 514:1990;15-21.
27. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
28. Malinge M., Colombel M.C., Bourin M. Mechanism of action of clonidine in the forced-swimming test in mice. Encephale. 15:1989;37-41.
29. Muir A.L., Burton J.L., Lawrie D.M. Circulatory effects at rest and exercise of clonidine, an imidazoline derivative with hypotensive properties. Lancet. 2:1969;181-184.
30. Ohata K., Murata T., Sakamoto H., Inoue K., Kobayashi M., Kohno S., Nagasaka Y., Kasai H. Pharmacological studies of guanabenz: effects of the central nervous system. Nippon Yakurigaku Zasshi. 80:1982;471-480.
31. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
32. Piletz J.E., Ivanov T.R., Sharp J.D., Ernsberger P., Chang C.H., Pickard R.T., Gold G., Roth B., Zhu H., Jones J.C., Baldwin J., Reis D.J. Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization. DNA Cell Biol. 19:2000;319-329.
33. 3H]clonidine binding to non-adrenergic sitres and alpha2-adrenergic receptors in human brain. Neuropsychopharmacology. 23:2000;697-708.
34. Piletz J.E., Sletten K. Non-adrenergic imidazoline binding sites on human platelets. J. Pharmacol. Exp. Ther. 267:1993;1493-1502.
35. 2 adrenoceptor subtypes. J. Pharmacol. Exp. Ther. 279:1996;694-702.
36. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229:1977;327-336.
37. Raddatz R., Lanier S.M. Relationship between imidazoline and guanidinium receptive sites and monoamine oxidase A and B. Neurochem. Int. 30:1997;109-117.
38. Roesler J.M., McCafferty J.P., DeMarinis R.M., Matthews W.D., Hieble J.P. Characterization of the antihypertensive activity of SKF 86466, a selective alpha-2 antagonist, in the rat. J. Pharmacol. Exp. Ther. 236:1986;1-7.
39. Ruffolo R.R. Jr., Nichols A.J., Stadel J.M., Hieble J.P. Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes. Annu. Rev. Pharmacol. Toxicol. 33:1993;243-279.
40. Rupp H., Jacob R. Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target? Med. Hypotheses. 44:1995;217-225.
41. 2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiatry. 4:1999;443-452.
42. 2-adrenoceptor agonist. Mol. Pharmacol. 51:1997;36-46.
43. Schachter M., Luszick J., Jager B., Verboom C., Sohlke E. Safety and tolerability of moxonidine in the treatment of hypertension. Drug Saf. 19:1998;191-203.
44. Scheinin M., Sallinen J., Haapalinna A. Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci. 68:2001;2277-2285.
45. Schmidt U., Frerick H., Kraft K., Schenk N., Low-Kroger A. Hypertension: A possible risk in road traffic. J. Cardiovasc. Pharmacol. 20:(Suppl. 4):1992;S50-S56.
46. Schramm N.L., McDonald M.P., Limbird L.E. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21:2001;4875-4882.
47. 1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res. 749:1997;335-339.
48. Shah R.S., Walker B.R., Vanov S.K., Helfant R.H. Guanabenz effects on blood pressure and non-invasive parameters of cardiac performance in patients with hypertension. Clin. Pharmacol. Ther. 19:1976;732-737.
49. Stec D.E., Davisson R.L., Haskell R.E., Davidson B.L., Sigmund C.D. Efficient liver-specific deletion of a floxed human angiotensinogen transgene by adenoviral delivery of cre-recombinase in vivo. J. Biol. Chem. 274:1999;21285-21290.
50. Steiner H., Fuchs S., Accili D. D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol. Behav. 63:1997;137-141.
51. Tan C.M., Wilson M.H., MacMillan L.B., Kobilka B.K., Limbird L.E. Heterozygous alpha2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. Proc. Natl. Acad. Sci. USA. 99:2002;12471-12476.
52. Tolentino-Silva F.P., Haxhiu M.A., Waldbaum S., Dreshaj I.A., Ernsberger P. Alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice. Brain Res. 862:2000;26-35.
53. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol. Biochem. Behav. 31:1988;959-962.
54. 1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine. J. Hypertens. 15:1997;117-125.
55. Vandergriff J., Kallman M.J., Rasmussen K. Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats. Biol. Psychiatry. 47:2000;874-879.
56. Von Voigtlander P.F., Triezenberg H.J., Losey E.G. Interactions between clonidine and antidepressant drugs: a method for identifying antidepressant-like agents. Neuropharmacology. 17:1978;375-381.
57. Wesnes K., Simpson P.M., Jansson B., Grahnen A., Weimann H.J., Kuppers H. Moxonidine and cognitive function: interactions with moclobemide and lorazepam. Eur. J. Clin. Pharmacol. 52:1997;351-358.
58. 2A-adrenoceptor transgenic mice. Br. J. Pharmacol. 126:1999;1522-1530.